Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altesa Secures IND Clearance for Vapendavir Development
Details : Vapendavir is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and reproducing. It is being studied for rhinovirus infections in people with COPD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Virtus Respiratory Research
Deal Size : Inapplicable
Deal Type : Inapplicable
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Virtus Respiratory Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral
Details : BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Altesa Biosciences
Deal Size : $130.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Altesa is granted the worldwide, exclusive right to develop, manufacture, and commercialize Vaxart’s proprietary formulation of Vapendavir.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 07, 2021
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Altesa Biosciences
Deal Size : $130.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinovirus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2017
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2016
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2015
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2014
Lead Product(s) : Vapendavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable